Meghan Dickman, M.D., is Clinical Associate Professor of Dermatology and Medical Director of Dermatology at Stanford ValleyCare. Dr. Dickman earned her B.S., with distinction, from the University of Michigan in 2006. She received her medical degree from the University of California, San Francisco. During medical school, Dr. Dickman was inducted into the Alpha Omega Alpha Honor Medical Society. She completed her dermatology residency at Stanford University and served as Chief Resident in her final year. She is board certified in dermatology by the American Board of Dermatology. Her professional focus is general medical dermatology, including acne, psoriasis, skin cancer, and dermatologic surgery.

Dr. Dickman also serves as the Medical Director of Dermatology for Stanford HealthCare-Valley Care and the Director of the East Bay Clinical Network for Stanford Dermatology, leading the department of dermatology's program building efforts and clinical operations in the East Bay region of the San Francisco Bay Area.

Clinical Focus

  • Dermatology
  • Acne
  • Psoriasis
  • Skin Cancer
  • Dermatologic Surgery
  • Telehealth
  • Artificial Intelligence
  • Machine Learning

Academic Appointments

Administrative Appointments

  • Director of East Bay Clinical Network, Department of Dermatology, Stanford School of Medicine (2019 - Present)
  • Director of Community Academic Practice Elective (CAPE), Department of Dermatology, Stanford University (2019 - Present)
  • Medical Director of Dermatology, Stanford Health Care - ValleyCare (2016 - Present)

Professional Education

  • Residency: Stanford University Dept of Dermatology (2016) CA
  • Internship: California Pacific Medical Center Internal Medicine Residency (2013) CA
  • Board Certification: American Board of Dermatology, Dermatology (2016)
  • Medical Education: University of California San Francisco (2012) CA

All Publications

  • Pernio-like eruption associated with COVID-19 in skin of color. JAAD case reports Daneshjou, R., Rana, J., Dickman, M., Yost, J. M., Chiou, A., Ko, J. 2020; 6 (9): 892–97

    View details for DOI 10.1016/j.jdcr.2020.07.009

    View details for PubMedID 32835046

  • Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm. Annals of hematology Schwede, M. n., Tan, I. T., Atibalentja, D. F., Dickman, M. M., Rieger, K. E., Mannis, G. N. 2020

    View details for DOI 10.1007/s00277-020-04276-z

    View details for PubMedID 32968828

  • Treatment of keratitis-ichthyosis-deafness (KID) syndrome in children: a case report and review of the literature DERMATOLOGIC THERAPY Patel, V., Sun, G., Dickman, M., Phuong Khuu, P., Teng, J. M. 2015; 28 (2): 89-93


    Keratitis-ichthyosis-deafness (KID) syndrome is a rare hereditary cornification disorder resulting from mutations in connexin 26, a protein important for intercellular communication. In addition to the characteristic clinical triad of congenital bilateral sensorineural hearing loss, keratitis, and erythrokeratoderma, affected individuals also suffer from chronic bacterial and fungal infections and have an increased risk of benign and malignant cutaneous tumors. Treatments with antibiotics, antifungals, and systemic retinoids have been reported with variable response. Ocular and skeletal toxicity from prolonged exposure to systemic retinoids is a major concern especially in children. We report a case of a 7-year-old boy with KID syndrome complicated by frequent infections who responded well to acitretin 0.5-1.0 mg/kg/day. The patient had significant improvement of the hyperkeratosis on the scalp, trunk, and extremities within 4 weeks after initiating treatment. The patient has been on treatment for over a year without notable ocular, skeletal, or laboratory side effects. A review of the literature focusing on therapeutic options for KID syndrome and concerns about safety and tolerability is presented.

    View details for DOI 10.1111/dth.12192

    View details for Web of Science ID 000352630800010

  • Aspirin Therapy in Venous Malformation: A Retrospective Cohort Study of Benefits, Side Effects, and Patient Experiences PEDIATRIC DERMATOLOGY Nguyen, J. T., Koerper, M. A., Hess, C. P., Dowd, C. F., Hoffman, W. Y., Dickman, M., Frieden, I. J. 2014; 31 (5): 556-560


    Venous malformations (VMs) are often painful and may enlarge over time. Chronic coagulopathy is common in VMs and may contribute to phleboliths and potentially to disease progression. Few studies have examined the effects of anticoagulation on VMs and to our knowledge none have examined the use of aspirin therapy. A survey was administered to patients and parents of patients with VMs who attended the University of California at San Francisco Vascular Anomalies Center over a 4-year period (2008-2012) to whom aspirin had been recommended. They were surveyed regarding whether they were taking aspirin and, if yes, whether aspirin had resulted in any appreciable benefit. Sixty-five letters were sent to potential subjects: 38 participated and 27 declined to participate or could not be contacted. Twenty-eight of the 38 had begun aspirin and 22 reported current use. Seventeen reported some benefit, including less aching (n = 2), less shooting pain (n = 15), less fullness and swelling (n = 13), and shrinking of the VM (n = 1). Discontinuation of aspirin was associated with worsening VM symptoms in five of six patients. Side effects were reported in 6 of 28 patients, including five episodes of minor bleeding or excessive bruising and one of nausea and vomiting. This study suggests that aspirin may be a beneficial treatment for VM, with a reduction in pain and soft tissue swelling and an acceptable side-effect profile, but the retrospective nature of the study and the small size of the cohort limited our conclusions. Larger prospective studies of aspirin for VM using clinical and laboratory outcome measures are needed to confirm these observations.

    View details for DOI 10.1111/pde.12373

    View details for Web of Science ID 000341811700004

    View details for PubMedID 25040175

  • Visual diagnosis: 13-year-old girl with pink papules. Allergic contact dermatitis with id reaction. Pediatrics in review Dickman, M. M., Frieden, I. J. 2013; 34 (6): e22-4

    View details for DOI 10.1542/pir.34-6-e22

    View details for PubMedID 23729779

  • Sacrococcygeal Teratoma Masquerading as Congenital Hemangioma PEDIATRIC DERMATOLOGY Mullen, M., Rabban, J., Frieden, I. J. 2013; 30 (1): 112-116


    Sacrococcygeal teratoma (SCT) is a rare tumor, present in approximately one in 40,000 live births. A small proportion of SCT have malignant potential, so prompt recognition and surgical resection are necessary. We report two cases of SCT initially misdiagnosed as hemangiomas because of their cutaneous appearance and in particular vascular stains overlying soft tissue mass. These two cases emphasize that SCT should be considered in the differential diagnosis of hemangiomas and in particular of congenital hemangiomas.

    View details for DOI 10.1111/j.1525-1470.2011.01703.x

    View details for Web of Science ID 000313727700018

    View details for PubMedID 22353016

  • The Relationship Between Hygiene and Microbial Burden in Atopic Dermatitis Risk Based on a Systematic Review ARCHIVES OF DERMATOLOGY Dickman, M., Dawson, A. L., Dellavalle, R. P. 2012; 148 (8): 936-938

    View details for Web of Science ID 000307740500012

    View details for PubMedID 22911191